Author

Mei Wang

OpenAlex ID: A5137463572

First‐line envafolimab plus recombinant human‐endostatin in advanced non–small cell lung cancer with PD‐L1 tumor proportion score ≥1% (Endouble): A multicenter, prospective, single‐arm, phase 2 trial

2026 · Changhong Dong, Liang Liu, et al. · Cancer

Works count: 1

Citation count:

H-index:

I10-index: